tbuckley/cabot-search huggingface dataset:
Consensus statement on the triage of critically ill patients. Society of Critical Care Medicine Ethics Committee
Authors: Charles L. Sprung, Marion Danis, Mary Ann Baily, Donald B. Chalfin, T. Forcht Dagi, Fidel Davila, Michael De Vita, H. Tristram Engelhardt, Ake Grenvik, Paul B. Hofmann, John W. Hoyt, W. Andrew Kofke, Joanne Lynn, Mary Faith Marshall, James J. McCartney, Robert M. Nelson, Nicholas Ninos, Russell C. Raphaely, Frank Reardon, Michael A. Rie, Stanley H. Rosenbaum, Henry Silverman, Frank D. Sottile, Allen Spanier, Avraham Steinberg, Rabbi Moses D. Tendier, Daniel Teres, Robert D. Truog, Thomas E. Wallace, Ginger Wlody, Timothy S. Yeh
Journal: JAMA (1994)

The demand for medical services such as critical care is likely to often exceed supply. In the setting of these constraining conditions, institutions and individual providers of critical care must use some moral framework for distributing the available resources efficiently and equitably. Guidelines are therefore provided for triage of critically ill patients. There are several general principles that should guide decision making: providers should advocate for patients; members of the provider team should collaborate; care must be restricted in an equitable system; decisions to give care should be based on expected benefit; mechanisms for alternative care should be planned; explicit policies should be written; prior public notification is necessary. Patients who are not expected to benefit from intensive care, such as those with imminently fatal illnesses or permanent unconsciousness, should not be placed in the intensive care unit. Hospitals should assign individuals the responsibility of intensive care triage, and a committee should oversee the performance of this responsibility to facilitate the most efficient and equitable use of intensive care.
Transposed Author Names
Authors: Florence Poizeau, Emmanuel Nowak, Alain Dupuy
Journal: JAMA Dermatology (2020)

studies can extend as far as "1 year before the outcome event." 3 Given the hypothesized immunological mechanism (immunomediated atherosclerotic plaque destabilization), a "just before" time window (if this means measured in hours or days) would have been inappropriate.Our 6-month risk period was justified by a hypothesized underlying biological mechanism, which was prespecified in the protocol.Beyond these considerations on the case-crossover design, we acknowledge that the observed events are rare, and the confidence intervals for the odds ratios are consequently large.Only large databases can evidence such differences for rare events, and we see this as a strength of our study.The unavailability of clinical and biological ("conventional") CV risk factors is a limitation of our study.However, the issue was to distinguish high-risk and lower-risk populations based on a prespecified hypothesis of an association between severe CV events and ustekinumab initiation that was anticipated to occur exclusively among patients with high baseline CV risk.We stress that our study addresses the general question of "why now" and not "why me" 4 for severe CV events among patients with high baseline CV risk at the time of ustekinumab initiation.Overall, our findings point to the need for clinicians to be aware of the risk of severe CV events within 6 months after ustekinumab initiation among patients with high baseline CV risk (while this does not preclude any type of longterm CV effect).They also point to the need for epidemiologists and immunologists to study similar risks with other biologics targeting the T-helper cell 17 pathway.
Les prémsturés
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rabies Prophylaxis: Pet Raccoon Scratch
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sedimentation Rate
Authors: W. Calwell
Journal: BMJ (1942)

<h3>Objective</h3> Inequality is deeply embedded in our economic structures—it is necessary to address these economic inequalities if we are to reduce health inequalities. An inclusive economic approach was conceptualised as a way to reduce these economic inequalities, although the attributes of this approach are unclear. Public health practitioners are increasingly asked to provide a health perspective on the economic recovery plans in the light of the COVID-19 pandemic. This paper aims to identify the attributes of an inclusive economy to enable the public health profession to influence an inclusive economic recovery. <h3>Approach</h3> We conducted a rapid review of grey and peer-reviewed literature to identify the attributes of an inclusive economy as currently defined in the literature. <h3>Attributes of an inclusive economy</h3> Twenty-two concepts were identified from 56 reports and articles. These were collapsed into four distinct attributes of an inclusive economy: (1) an economy that is designed to deliver inclusion and equity, (2) equitable distribution of the benefits from the economy (eg, assets, power, value), (3) equitable access to the resources needed to participate in the economy (eg, health, education), and (4) the economy operates within planetary boundaries. <h3>Conclusion</h3> As economies are (re)built following the COVID-19 pandemic, these attributes of an inclusive economy—based on the current literature—can be used to develop, and then monitor progress of, economic policy that will reduce health inequalities, improve health and mitigate against climate change.
Abstract 393: Cronos Titin in Human Heart Development
Authors: Rebecca J Zaunbrecher, Xiulan Yang, Hans Reinecke, Lil Pabon, Michael Regnier, Charles E Murry
Journal: Circulation Research (2017)

Titin is a giant myofibrillar protein that provides passive tension and facilitates sarcomere formation in striated muscle, where it spans from the Z-disk to the M-line. Recently, an alternative start site has been identified in the titin gene that is predicted to allow for expression of a novel isoform, Cronos, that is ~2/3 the size of full-length titin and lacks the Z-disk and most of the I-band domains. Because the start site for this isoform is spliced out of full-length titin transcripts, we are able to determine the expression levels of Cronos compared to full-length titin. Reverse-transcription followed by quantitative PCR using primers specific to this region indicate Cronos transcript levels are higher in human fetal ventricle and atrial tissue (days 90-105) than in adult samples, while full-length titin transcripts are higher in adult than fetal cardiac tissue. Additionally, human ventricular tissue stained with a custom antibody raised to recognize this specific region of Cronos titin indicated high levels of protein expression and integration into myofibrils in early fetal samples (days 54 and 81), while this novel isoform was nearly undetectable in later fetal (day 130) and adult tissue. The Cronos titin transcript and protein were also detected in high quantities in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), which are believed to have a fetal level of maturity. Based on these data, we conclude that Cronos is predominantly a fetal isoform of titin. Future experiments will investigate the effects of a Cronos titin knockdown in hiPSC-CMs during and after differentiation to establish its functional role in human heart development.
THE SPREAD OF INSANITY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Authors: None UK Prospective Diabetes Study Group
Journal: BMJ (1998)

Objective: To determine whether tight control of blood pressure with either a β blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes.
Robert Gooch (1784-1830) Psychiatric Midwife
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DNA probes demonstrate utility in diagnosis, treatment monitoring
Authors: B. Merz
Journal: JAMA (1988)

THE FIRST DNA PROBES for oncogenes are awaiting Food and Drug Administration approval for use in cancer diagnosis. They may become to the 1990s what cytogenetics was to the 1980s and histology to the previous decades: the best means of providing a specific diagnosis of several forms of cancer. Although all three techniques provide a physiological indication of cellular changes related to carcinogenesis, each demonstrates something different. Histology detects gross cellular abnormalities; cytogenetics reveals alterations in banded chromosomes; molecular analysis uncovers changes in specific regions of DNA. Molecular analysis relies on the use of DNA probes, synthetic copies of specific genes that are radioactively labeled. When these probes are added to denatured DNA samples in a procedure called Southern blotting, they will hybridize with the gene whenever it is present. Thus, they can be used to indicate a gene's chromosomal location as well as the number of times it appears
Influenza—United States Update on Activity
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WHY SCIENTISTS ARE POOR WRITERS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Standards for Medical Expert Testimony
Authors: L. Noah
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening for Lung Cancer With Low-Dose Helical Computed Tomography: Anti-Lung Cancer Association Project
Authors: T. Sobue
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Because efficacy of lung cancer screening using chest x-ray is controversial and insufficient, other screening modalities need to be developed. To provide data on screening performance of low-dose helical computed tomography (CT) scanning and its efficacy in terms of survival, a one-arm longitudinal screening project was conducted. PATIENTS AND METHODS: A total of 1,611 asymptomatic patients aged 40 to 79 years, 86% with smoking history, were screened by low-dose helical CT scan, chest x-ray, and 3-day pooled sputum cytology with a 6-month interval. RESULTS: At initial screening, the proportions of positive tests were 11.5%, 3.4%, and 0.8% with low-dose helical CT scan, chest x-ray, and sputum cytology, respectively. In 1,611 participants, 14 (0.87%) cases of lung cancer were detected, with 71% being stage IA disease and a mean tumor diameter of 19.8 mm. At repeated screening, the proportions of positive tests were 9.1%, 2.6%, and 0.7% with low-dose helical CT, chest x-ray, and sputum cytology, respectively. In 7,891 examinations, 22 (0.28%) cases of lung cancer were detected, with 82% being stage IA disease and a mean tumor diameter of 14.6 mm. The 5-year survival rate for screen-detected lung cancer was 76.2% and 64.9% for initial and repeated screening, respectively. CONCLUSION: Screening with low-dose helical CT has potential to improve screening efficacy in terms of reducing lung cancer mortality. An evaluation of efficacy using appropriate methods is urgently required.
THE RELATIONSHIP BETWEEN GENERAL PARALYSIS AND TABES DORSALIS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Murder in medical education
Authors: P. C. Anderson
Journal: JAMA (1968)

The mental features discoursed of as the analytical are, in themselves, but little susceptible of analysis. We appreciate them only in their effects. We know of them, among other things, that they are always to their possessor, when inordinately possessed, a source of the liveliest enjoyment. As the strong man exults in his physical ability, delighting in such exercises as call his muscles into action, so glories the analyst in that moral activity which<i>disentangles</i>. He derives pleasure from even the most trivial occupations bringing his talent into play. He is fond of enigmas, of conundrums, hieroglyphics; exhibiting in his solutions of each a degree of acumen which appears to the ordinary apprehension praeternatural. His results, brought about by the very soul and essence of method, have, in truth, the whole air of intuition. Edgar A. Poe, "The Murders in the Rue Morgue," 1841
Heparin Modifies the Immunogenicity of Positively-Charged Proteins.
Authors: Gowthami M. Arepally, Shalini Chudasama, Benjamin Espinasse, Fred Hwang, Rui Qi, Manali Joglekar, Galyna Afonina, Mark Wiesner, Ian Welsby, Thomas Ortel
Journal: Blood (2010)
<i>Circulation:</i> Clinical Summaries
Journal: Circulation (2010)

Chronic kidney disease (CKD) is a risk factor for myocardial infarction (MI) and death.We sought to characterize the association between CKD severity and short-term outcomes and the use of in-hospital evidence-based therapies among patients with STsegment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI) using the Acute Coronary Treatment and Intervention Outcomes Network registry, a nationwide sample of STEMI and NSTEMI patients admitted to hospitals in the United States.Overall, 30.5% and 42.9% of patients with STEMI and NSTEMI, respectively, had CKD.Regardless of MI type, patients with progressively more severe CKD had higher rates of death.In addition, patients with progressively more severe CKD were less likely to receive immediate evidence-based therapies including aspirin, ␤-blockers, or clopidogrel, were less likely to undergo any reperfusion (STEMI) or revascularization (NSTEMI), and had higher rates of bleeding.We conclude that a large proportion of patients presenting with STEMI or NSTEMI have CKD and have increased in-hospital mortality rates.These patients receive fewer evidence-based therapies.Additional research to define optimal post-MI care in patients with CKD is warranted.See p 357.